The direct thrombin inhibitors (argatroban, bivalirudin and lepirudin) and the indirect Xa-inhibitor (danaparoid) increase fibrin network porosity and thus facilitate fibrinolysis
暂无分享,去创建一个
M. Blombäck | N. Bark | H. Johnsson | Shu He | N. Wallén | N. H. Wallén
[1] Bernard Pirotte,et al. Is thrombin generation the new rapid, reliable and relevant pharmacological tool for the development of anticoagulant drugs? , 2009, Pharmacological research.
[2] T. Kohlmann,et al. Heparin‐induced thrombocytopenia – therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4–heparin complexes , 2008, Journal of thrombosis and haemostasis : JTH.
[3] M. Blombäck,et al. In Vitro Effects of Argatroban, Lepirudin, Bivalirudin, and Danaparoid on Fibrin Gel Permeability , 2008 .
[4] A. Greinacher,et al. The direct thrombin inhibitor hirudin , 2008, Thrombosis and Haemostasis.
[5] F. Depasse,et al. Three different patterns of calibrated automated thrombogram obtained with six different anticoagulants , 2007, Journal of thrombosis and haemostasis : JTH.
[6] M. Blombäck,et al. A global assay of haemostasis which uses recombinant tissue factor and tissue-type plasminogen activator to measure the rate of fibrin formation and fibrin degradation in plasma , 2007, Thrombosis and Haemostasis.
[7] R. de Caterina,et al. Anticoagulants in heart disease: current status and perspectives. , 2007, European heart journal.
[8] J. Soria,et al. Clot structure modification by fondaparinux and consequence on fibrinolysis: A new mechanism of antithrombotic activity , 2006, Thrombosis and Haemostasis.
[9] P. Morange,et al. Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. , 2006, Blood.
[10] R. Carroll,et al. Measurement of Patients' Bivalirudin Plasma Levels by a Thrombelastograph® Ecarin Clotting Time Assay: A Comparison to a Standard Activated Clotting Time , 2006, Anesthesia and analgesia.
[11] V. Durkalski,et al. Evaluation of Treatment with Direct Thrombin Inhibitors in Patients with Heparin‐Induced Thrombocytopenia , 2006, Pharmacotherapy.
[12] Alisa S Wolberg,et al. High dose factor VIIa improves clot structure and stability in a model of haemophilia B , 2005, British journal of haematology.
[13] Jörg Ingrid,et al. Treatment of Patients with a History of Heparin-Induced Thrombocytopenia and Anti-Lepirudin Antibodies with Argatroban , 2005, Journal of Thrombosis and Thrombolysis.
[14] M. Blombäck,et al. Modifications of flow measurement to determine fibrin gel permeability and the preliminary use in research and clinical materials , 2005, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[15] N. Kleiman,et al. Pharmacokinetics and Pharmacodynamics of Argatroban in Combination With a Platelet Glycoprotein IIB/IIIA Receptor Antagonist in Patients Undergoing Percutaneous Coronary Intervention , 2004, Journal of clinical pharmacology.
[16] Ingemar Nilsson,et al. A new oral anticoagulant: the 50-year challenge , 2004, Nature Reviews Drug Discovery.
[17] M. Blombäck,et al. The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX , 2003, Journal of thrombosis and haemostasis : JTH.
[18] A. Lincoff,et al. Correlation of point-of-care ecarin clotting time versus activated clotting time with bivalirudin concentrations. , 2003, The American journal of cardiology.
[19] M. Carrier,et al. Heparin versus danaparoid in off-pump coronary bypass grafting: results of a prospective randomized clinical trial. , 2003, The Journal of thoracic and cardiovascular surgery.
[20] S. Béguin,et al. The Calibrated Automated Thrombogram (CAT): a universal routine test for hyper- and hypocoagulability , 2002, Pathophysiology of Haemostasis and Thrombosis.
[21] S. Carlsson,et al. Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor. , 2001, Thrombosis research.
[22] M. Turina,et al. [R-hirudin (lepirudin, refludan) as an alternative anticoagulant in heparin-induced thrombocytopenia during cardiopulmonary bypass connection]. , 2000, Swiss medical weekly.
[23] J. Soria,et al. Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[24] J. Soria,et al. Abnormal Fibrin Clot Architecture in Nephrotic Patients Is Related to Hypofibrinolysis: Influence of Plasma Biochemical Modifications , 1999, Thrombosis and Haemostasis.
[25] D. Hoppensteadt,et al. Clinical laboratory monitoring of a synthetic antithrombin agent, argatroban, using high performance liquid chromatography and functional methods. , 1999, International angiology : a journal of the International Union of Angiology.
[26] M. Wilde,et al. Lepirudin: a review of its potential place in the management of thrombotic disorders. , 1998, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.
[27] G. Wimmer-Greinecker,et al. Heparin-Induced Thrombocytopenia Type II: Perioperative Management Using Danaparoid in a Coronary Artery Bypass Patient with Renal Failure , 1997, The Thoracic and cardiovascular surgeon.
[28] B. Blombäck. Fibrinogen and fibrin--proteins with complex roles in hemostasis and thrombosis. , 1996, Thrombosis research.
[29] P. A. von dem Borne,et al. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. , 1995, Blood.
[30] K. Carlsson,et al. Fibrin in human plasma: gel architectures governed by rate and nature of fibrinogen activation. , 1994, Thrombosis research.
[31] J. Cardot,et al. Pharmacokinetics of rec-hirudin in healthy volunteers after intravenous administration , 1994, Journal of Pharmacokinetics and Biopharmaceutics.
[32] M. Blombäck,et al. Fibrin Gel Network Characteristics and Coronary Heart Disease: Relations to Plasma Fibrinogen Concentration, Acute Phase Protein, Serum Lipoproteins and Coronary Atherosclerosis , 1992, Thrombosis and Haemostasis.
[33] A. Azhar,et al. Studies on fibrin network structure in human plasma. Part II--Clinical application: diabetes and antidiabetic drugs. , 1991, Thrombosis research.
[34] A Liljeborg,et al. Native fibrin gel networks observed by 3D microscopy, permeation and turbidity. , 1989, Biochimica et biophysica acta.
[35] L. Boggio,et al. Argatroban use in heparin-induced thrombocytopenia. , 2008, Expert opinion on pharmacotherapy.
[36] W. Gray,et al. Point-of-care ecarin clotting time versus activated clotting time in correlation with bivalirudin concentration. , 2004, Thrombosis research.